---
title: "Novonesis delivered strong start to the year with 7% organic sales growth in Q1"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285161749.md"
description: "In Q1 2026, Novonesis reported a 7% organic sales growth and an adjusted EBITDA margin of 37.8%. The growth was broad-based across all sales areas, with Developed Markets growing 8% and Emerging Markets 4%. The company confirmed its 2026 outlook, expecting organic sales growth of 5-7% and an adjusted EBITDA margin of 37-38%. Additionally, Novonesis completed a EUR 1.7 billion bond issuance and acquired a production facility in Thailand to support its growth strategy."
datetime: "2026-05-05T06:18:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285161749.md)
  - [en](https://longbridge.com/en/news/285161749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285161749.md)
---

# Novonesis delivered strong start to the year with 7% organic sales growth in Q1

**COPENHAGEN, Denmark – May 5, 2026.** In the first quarter of 2026, Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.8%.

Ester Baiget, President & CEO:

_“The year started strong with 7% organic sales growth against a high comparable. We delivered growth across all sales areas and in both Developed and Emerging markets, while achieving an adjusted EBITDA margin of 37.8%. Quarter after quarter, our results demonstrate the strength and resilience of our business model. Even with increased global uncertainty, we are confident in our full-year outlook and in our 2030 targets, including a 6–9% organic sales growth CAGR. As the world continues to change, the relevance and demand for biosolutions continue to grow."_

**Highlights of our Q1 2026 results:**

• Strong broad-based organic sales growth of 7% including ~1.5 pp effect from exiting certain countries. Price and revenue synergies contributed ~1 pp each.

• Food & Health Biosolutions grew 9% organically including ~3 pp effect from exiting certain countries; Planetary Health Biosolutions grew 5% organically.

• Developed Markets grew 8% organically and Emerging Markets 4% including ~3 pp effect from exiting certain countries.

• Adjusted EBITDA margin at 37.8% including a significant year-on-year currency headwind.

• Adjusted net profit excl. PPA increased 8%.

• NIBD/EBITDA at 2.0x, and free cash flow before acquisitions increased 9% to EUR 74 million. CAPEX ratio at 8.3%.

• Successful inaugural bond issuance of EUR 1.7 billion completed to refinance a bridge loan facility.

• Acquisition of a production facility in Thailand to support growth journey.

• 2026 outlook confirmed:Organic sales growth is expected to be in the range of 5-7% which includes a close to 1 pp effect from exiting certain countries. Adjusted EBITDA margin expected to be between 37-38%.

Here is the link to the investor call on Novonesis Q1 2026 results: https://getvisualtv.net/stream/?novonesis-interim-report-q1-2026

**Get in touch**

**Media relations**

Benjamin Hjorth

Senior Press Manager

media-relations@novonesis.com

+45 30 77 13 12

Tobias Bjorklund

Head of Investor Relations

tobb@novonesis.com

### Related Stocks

- [NVX.AU](https://longbridge.com/en/quote/NVX.AU.md)
- [NVNXF.US](https://longbridge.com/en/quote/NVNXF.US.md)

## Related News & Research

- [The best biotech stocks to buy in 2026](https://longbridge.com/en/news/290106847.md)
- [Biovica says new Phase III data show DiviTum TKa captures treatment-specific biological response in metastatic breast cancer](https://longbridge.com/en/news/290005590.md)
- [Is the 2026 Soybean Rally Over?](https://longbridge.com/en/news/290237132.md)
- [The Rise of Biometrics for Retail Payments](https://longbridge.com/en/news/289802278.md)
- [22:28 ETVIA Investors Have Opportunity to Lead Via Transportation, Inc. Securities Lawsuit](https://longbridge.com/en/news/289852803.md)